nivolumab,ipilimumab
bms
['9la', 'cm9la']
cm9la 4 year data shows the expected. after 3 years little has changed. results in pd-l1 negative patients are quite impressive. 2% decrease in os from year 3 to year 4. high expressos and even pd-l1 + patients did not seem to benefit that much from combo io. #asco23 
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.